P3 Health Partners (NASDAQ:PIII – Free Report) had its price target reduced by TD Cowen from $13.00 to $4.00 in a research report released on Wednesday,Benzinga reports. They currently have a hold rating on the stock.
A number of other research firms also recently weighed in on PIII. Weiss Ratings downgraded P3 Health Partners from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Lake Street Capital reiterated a “buy” rating and issued a $23.00 price target on shares of P3 Health Partners in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $13.67.
Get Our Latest Analysis on PIII
P3 Health Partners Stock Down 22.8%
Shares of NASDAQ PIII opened at $2.61 on Wednesday. The firm has a market cap of $18.95 million, a PE ratio of -0.11 and a beta of 1.81. P3 Health Partners has a 12-month low of $1.52 and a 12-month high of $16.89. The company’s fifty day simple moving average is $5.79 and its 200 day simple moving average is $6.58.
P3 Health Partners (NASDAQ:PIII – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($3.96) by $4.03. The company had revenue of $396.34 million during the quarter, compared to the consensus estimate of $384.95 million.
Institutional Investors Weigh In On P3 Health Partners
An institutional investor recently bought a new position in P3 Health Partners stock. Lido Advisors LLC purchased a new stake in P3 Health Partners Inc. (NASDAQ:PIII – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned approximately 0.15% of P3 Health Partners as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 7.75% of the company’s stock.
P3 Health Partners Company Profile
P3 Health Partners Inc. is a physician-led healthcare company focused on value-based care for Medicare Advantage beneficiaries. The company works with primary care physicians, specialists, health plans and community organizations to coordinate care and improve health outcomes while addressing patients’ medical and social needs. Its services include primary care support, care coordination, chronic-condition management, preventive care, medication management and patient navigation. P3’s model uses an integrated care team and data-driven clinical programs to help physicians manage the health of senior populations across the care continuum.
Further Reading
- Five stocks we like better than P3 Health Partners
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.
